Efinopegdutide (MK-6024)
Quick summary
A long-acting dual GLP-1/glucagon receptor agonist in clinical development, studied in liver-fat research. Research focus: GLP-1/glucagon co-agonism and hepatic fat metabolism. SRP's starting dose for this compound is still pending.
Overview
A long-acting dual GLP-1/glucagon receptor agonist in clinical development, studied in liver-fat research.
Looking for research material? Simple Research Peptides lists Efinopegdutide (MK-6024) for laboratory research use.
Mechanism
A PEGylated, balanced GLP-1/glucagon co-agonist.
Research areas
- GLP-1/glucagon co-agonism
- hepatic fat metabolism
Storage & reconstitution
Supplied as a freeze-dried (lyophilized) powder in a sealed vial. Unopened vials are generally kept cold and away from light. Labs usually reconstitute it with bacteriostatic or sterile water, letting the liquid run down the vial wall and swirling gently instead of shaking. The solution is then kept refrigerated.
Recommended starting dose (low and slow)
| Starting dose | Pending - to be added by SRP |
|---|---|
| Frequency | Pending - to be added by SRP |
| Reconstitution | Pending - to be added by SRP |
Route and timing
Route: Subcutaneous injection after reconstitution is the route most often described in research protocols.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: Not well characterized in published research.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks; fasting glucose, HbA1c and lipid panel; lipase where GLP-1 or amylin-pathway compounds are involved.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only.
Frequently asked questions
What is Efinopegdutide (MK-6024) studied for?
In research it is studied for GLP-1/glucagon co-agonism and hepatic fat metabolism. A PEGylated, balanced GLP-1/glucagon co-agonist.
How is Efinopegdutide (MK-6024) given in research?
Subcutaneous injection after reconstitution is the route most often described in research protocols. SRP has not yet published a frequency for this compound.
What amount should a researcher start with?
SRP has not yet published a starting dose for Efinopegdutide (MK-6024). Contact SRP before starting any research protocol, and do not guess.
Related peptides
Last updated: October 19, 2026